Establishment of novel cardiorenal linkage suppressive therapy by KATP channel opener Nicorandil

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09072
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Gifu University
• Principal Investigator: Nishigaki kazuhiko 岐阜大学, 大学院医学系研究科, 准教授 (60198447)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 造影剤腎症 / ニコランジル / シスタチンＣ / 経皮的冠動脈インターベンション

Outline of Final Research Achievements

We conducted a prospective randomized trial to assess the protective effect of continuous intravenous infusion of nicorandil against contrast-induced nephropathy (CIN) in patients with poor renal function. We randomly assigned patients who would subsequently undergo elective percutaneous coronary intervention (PCI) and who had a high serum cystatin C level to a saline group or a nicorandil group. The average percent increases in serum creatinine and cystatin C following PCI were significantly smaller in the nicorandil group than the saline group, and the average percent decline in the estimated glomerular filtration rate was smaller in the nicorandil group. Correspondingly, the incidence of CIN was dramatically lower in the nicorandil group than the saline group. Univariate regression analysis revealed nicorandil treatment to be the only significant predictor of CIN development. Nicorandil strongly prevents CIN in patients with poor renal function undergoing PCI.

Free Research Field

循環器内科学